(Q26823768)

Erratum to GLP-1 receptor agonists: a review of head-to-head clinical studies

corrigendum / erratum

0 references

author name string

J. M. Trujillo

series ordinal

1

1 reference

W. Nuffer

series ordinal

2

1 reference

S. L. Ellis

series ordinal

3

1 reference

language of work or name

1 reference

February 2015

1 reference

Therapeutic advances in endocrinology and metabolism

published in

1 reference

volume

6

1 reference

issue

1

1 reference

page(s)

19-28

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4321870

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

31 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042018814559725

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25678953